2019 Q2 Form 10-Q Financial Statement
#000143853319000011 Filed on May 07, 2019
Income Statement
| Concept | 2019 Q2 | 2019 Q1 | 2018 Q1 |
|---|---|---|---|
| Revenue | $44.71M | $39.57M | $38.43M |
| YoY Change | 8.15% | 2.96% | 14.31% |
| Cost Of Revenue | $979.0K | $1.017M | $1.613M |
| YoY Change | -16.89% | -36.95% | 127.5% |
| Gross Profit | $43.73M | $38.55M | $36.82M |
| YoY Change | 8.89% | 4.71% | 11.87% |
| Gross Profit Margin | 97.81% | 97.43% | 95.8% |
| Selling, General & Admin | $38.97M | $32.67M | $26.47M |
| YoY Change | 55.26% | 23.43% | 14.51% |
| % of Gross Profit | 89.12% | 84.74% | 71.89% |
| Research & Development | $37.93M | $33.44M | $24.64M |
| YoY Change | 10.08% | 35.75% | 18.1% |
| % of Gross Profit | 86.75% | 86.75% | 66.91% |
| Depreciation & Amortization | $4.840M | $4.901M | $4.348M |
| YoY Change | 4.31% | 12.72% | 1.49% |
| % of Gross Profit | 11.07% | 12.71% | 11.81% |
| Operating Expenses | $81.24M | $77.80M | $56.34M |
| YoY Change | 29.16% | 38.08% | 17.31% |
| Operating Profit | -$36.53M | -$38.23M | -$17.91M |
| YoY Change | 69.43% | 113.42% | 24.32% |
| Interest Expense | -$4.817M | -$4.865M | -$1.155M |
| YoY Change | 355.72% | 321.21% | 775.0% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$2.103M | -$2.348M | -$237.0K |
| YoY Change | 249.34% | 890.72% | -118.9% |
| Pretax Income | -$38.63M | -$40.58M | -$18.15M |
| YoY Change | 74.32% | 123.57% | 37.97% |
| Income Tax | $69.00K | $401.0K | $229.0K |
| % Of Pretax Income | |||
| Net Earnings | -$38.70M | -$40.98M | -$18.38M |
| YoY Change | 73.32% | 122.97% | 65.72% |
| Net Earnings / Revenue | -86.57% | -103.56% | -47.82% |
| Basic Earnings Per Share | -$0.99 | -$0.46 | |
| Diluted Earnings Per Share | -$922.3K | -$0.99 | -$0.46 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 41.44M shares | 41.41M shares | 39.66M shares |
| Diluted Shares Outstanding | 41.41M shares | 39.66M shares |
Balance Sheet
| Concept | 2019 Q2 | 2019 Q1 | 2018 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $298.4M | $270.7M | $264.0M |
| YoY Change | 16.7% | 2.52% | 6.39% |
| Cash & Equivalents | $75.66M | $69.84M | $61.12M |
| Short-Term Investments | $222.7M | $200.8M | $202.9M |
| Other Short-Term Assets | $10.60M | $9.600M | $4.600M |
| YoY Change | 92.73% | 108.7% | -33.33% |
| Inventory | $5.050M | $5.571M | $5.142M |
| Prepaid Expenses | |||
| Receivables | $15.50M | $12.71M | $12.98M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $457.0M | $475.5M | $286.8M |
| YoY Change | 63.85% | 65.8% | -11.04% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $3.015M | $2.995M | $3.042M |
| YoY Change | -12.74% | -1.55% | 25.29% |
| Goodwill | $936.0K | $936.0K | $936.0K |
| YoY Change | 0.0% | 0.0% | 0.0% |
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $15.00M | $15.00M | $15.00M |
| YoY Change | 0.0% | 0.0% | |
| Other Assets | $12.70M | $13.47M | $6.457M |
| YoY Change | 137.38% | 108.63% | 76.37% |
| Total Long-Term Assets | $190.6M | $192.2M | $214.0M |
| YoY Change | -10.21% | -10.2% | 13.84% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $457.0M | $475.5M | $286.8M |
| Total Long-Term Assets | $190.6M | $192.2M | $214.0M |
| Total Assets | $647.6M | $667.7M | $500.8M |
| YoY Change | 31.85% | 33.32% | -1.88% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $12.52M | $7.627M | $9.423M |
| YoY Change | 59.54% | -19.06% | 101.73% |
| Accrued Expenses | $50.56M | $46.62M | $31.64M |
| YoY Change | 43.34% | 47.32% | 4.81% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | $22.50M | |
| YoY Change | -100.0% | ||
| Total Short-Term Liabilities | $90.59M | $104.1M | $56.53M |
| YoY Change | -12.47% | 84.12% | -26.16% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $199.9M | $197.5M | $45.20M |
| YoY Change | 336.95% | 1.35% | |
| Other Long-Term Liabilities | $22.10M | $23.41M | $4.617M |
| YoY Change | 352.91% | 407.08% | 19.7% |
| Total Long-Term Liabilities | $22.10M | $23.41M | $4.617M |
| YoY Change | 352.91% | 407.08% | 19.7% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $90.59M | $104.1M | $56.53M |
| Total Long-Term Liabilities | $22.10M | $23.41M | $4.617M |
| Total Liabilities | $370.5M | $382.0M | $201.3M |
| YoY Change | 82.37% | 89.73% | -3.88% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$349.7M | -$311.0M | -$185.7M |
| YoY Change | 68.09% | 67.46% | 43.95% |
| Common Stock | $626.0M | $596.6M | $486.7M |
| YoY Change | 25.91% | 22.59% | 13.09% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $277.1M | $285.7M | $299.5M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $647.6M | $667.7M | $500.8M |
| YoY Change | 31.85% | 33.32% | -1.88% |
Cashflow Statement
| Concept | 2019 Q2 | 2019 Q1 | 2018 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$38.70M | -$40.98M | -$18.38M |
| YoY Change | 73.32% | 122.97% | 65.72% |
| Depreciation, Depletion And Amortization | $4.840M | $4.901M | $4.348M |
| YoY Change | 4.31% | 12.72% | 1.49% |
| Cash From Operating Activities | -$19.11M | -$20.49M | -$14.73M |
| YoY Change | 592.39% | 39.08% | 332.08% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$3.390M | $19.00K | $39.00K |
| YoY Change | -9.12% | -51.28% | -95.35% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $28.62M | -$7.430M | -$12.60M |
| YoY Change | -9.57% | -41.03% | -249.29% |
| Cash From Investing Activities | $25.23M | -$11.41M | -$20.85M |
| YoY Change | -9.6% | -45.27% | -604.87% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -320.0K | -$1.110M | -$2.702M |
| YoY Change | -110.39% | -58.92% | -1901.33% |
| NET CHANGE | |||
| Cash From Operating Activities | -19.11M | -$20.49M | -$14.73M |
| Cash From Investing Activities | 25.23M | -$11.41M | -$20.85M |
| Cash From Financing Activities | -320.0K | -$1.110M | -$2.702M |
| Net Change In Cash | 5.800M | -$33.04M | -$38.28M |
| YoY Change | -79.45% | -13.69% | -4499.66% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$19.11M | -$20.49M | -$14.73M |
| Capital Expenditures | -$3.390M | $19.00K | $39.00K |
| Free Cash Flow | -$15.72M | -$20.51M | -$14.77M |
| YoY Change | -1720.62% | 38.84% | 247.76% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2019Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2019Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2019Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2019 | |
| CY2019Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2019-03-31 | |
| CY2019Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2019Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001438533 | |
| CY2019Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
41439478 | shares |
| CY2019Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2019Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | |
| CY2019Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
Retrophin, Inc. | |
| CY2019Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
false | |
| CY2019Q1 | dei |
Trading Symbol
TradingSymbol
|
rtrx | |
| CY2018Q4 | rtrx |
Accrued Liabilities Miscellaneous
AccruedLiabilitiesMiscellaneous
|
4475000 | USD |
| CY2019Q1 | rtrx |
Accrued Liabilities Miscellaneous
AccruedLiabilitiesMiscellaneous
|
1966000 | USD |
| CY2018Q4 | rtrx |
Accrued Liabilities Researchand Development Current
AccruedLiabilitiesResearchandDevelopmentCurrent
|
16515000 | USD |
| CY2019Q1 | rtrx |
Accrued Liabilities Researchand Development Current
AccruedLiabilitiesResearchandDevelopmentCurrent
|
17955000 | USD |
| CY2018Q4 | rtrx |
Accrued Liabilities Selling Generaland Administrative Current
AccruedLiabilitiesSellingGeneralandAdministrativeCurrent
|
2990000 | USD |
| CY2019Q1 | rtrx |
Accrued Liabilities Selling Generaland Administrative Current
AccruedLiabilitiesSellingGeneralandAdministrativeCurrent
|
3812000 | USD |
| CY2018Q4 | rtrx |
Accrued Royaltyand Contingent Consideration
AccruedRoyaltyandContingentConsideration
|
6805000 | USD |
| CY2019Q1 | rtrx |
Accrued Royaltyand Contingent Consideration
AccruedRoyaltyandContingentConsideration
|
6042000 | USD |
| CY2018Q4 | rtrx |
Acquisition Related Contingent Consideration
AcquisitionRelatedContingentConsideration
|
19350000 | USD |
| CY2019Q1 | rtrx |
Acquisition Related Contingent Consideration
AcquisitionRelatedContingentConsideration
|
19000000 | USD |
| CY2018Q4 | rtrx |
Acquisition Related Contingent Consideration Noncurrent
AcquisitionRelatedContingentConsiderationNoncurrent
|
73650000 | USD |
| CY2019Q1 | rtrx |
Acquisition Related Contingent Consideration Noncurrent
AcquisitionRelatedContingentConsiderationNoncurrent
|
57000000 | USD |
| CY2018Q1 | rtrx |
Business Combination Option Agreement Contingent Consideration
BusinessCombinationOptionAgreementContingentConsideration
|
25000000 | USD |
| CY2018Q1 | rtrx |
Business Combination Option Agreement Percent Of Consideration Paid In Cash If Share Price Falls Below Share Price Threshold
BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold
|
1 | |
| CY2018Q1 | rtrx |
Business Combination Option Agreement Purchase Price
BusinessCombinationOptionAgreementPurchasePrice
|
65000000 | USD |
| CY2018Q1 | rtrx |
Business Combination Option Agreement Purchase Price Percent Transfered In Cash
BusinessCombinationOptionAgreementPurchasePricePercentTransferedInCash
|
0.2 | |
| CY2018Q1 | rtrx |
Business Combination Option Agreement Purchase Price Percent Transferred By Issuance Of Equity
BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity
|
0.8 | |
| CY2018Q4 | rtrx |
Business Combination Option Agreement Share Price
BusinessCombinationOptionAgreementSharePrice
|
21.40 | |
| CY2018Q1 | rtrx |
Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
|
3627000 | USD |
| CY2019Q1 | rtrx |
Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
|
3169000 | USD |
| CY2018Q1 | rtrx |
Classof Warrantor Right Common Stock Issued Upon Exerciseof Warrants
ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants
|
168612 | shares |
| CY2018Q4 | rtrx |
Debt Securities Available For Sale Unrealized Gain Current
DebtSecuritiesAvailableForSaleUnrealizedGainCurrent
|
0 | USD |
| CY2019Q1 | rtrx |
Debt Securities Available For Sale Unrealized Gain Current
DebtSecuritiesAvailableForSaleUnrealizedGainCurrent
|
48000 | USD |
| CY2018Q4 | rtrx |
Debt Securities Available For Sale Unrealized Gain Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent
|
22000 | USD |
| CY2019Q1 | rtrx |
Debt Securities Available For Sale Unrealized Gain Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent
|
436000 | USD |
| CY2018Q4 | rtrx |
Debt Securities Available For Sale Unrealized Loss Current
DebtSecuritiesAvailableForSaleUnrealizedLossCurrent
|
662000 | USD |
| CY2019Q1 | rtrx |
Debt Securities Available For Sale Unrealized Loss Current
DebtSecuritiesAvailableForSaleUnrealizedLossCurrent
|
213000 | USD |
| CY2018Q4 | rtrx |
Debt Securities Available For Sale Unrealized Loss Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent
|
639000 | USD |
| CY2019Q1 | rtrx |
Debt Securities Available For Sale Unrealized Loss Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent
|
84000 | USD |
| CY2018Q4 | rtrx |
Debt Securities Availableforsale Amortized Cost Basis Current
DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent
|
209137000 | USD |
| CY2019Q1 | rtrx |
Debt Securities Availableforsale Amortized Cost Basis Current
DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent
|
200999000 | USD |
| CY2018Q4 | rtrx |
Debt Securities Availableforsale Amortized Cost Basis Noncurrent
DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent
|
160810000 | USD |
| CY2019Q1 | rtrx |
Debt Securities Availableforsale Amortized Cost Basis Noncurrent
DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent
|
176622000 | USD |
| CY2019Q1 | rtrx |
Development Funding
DevelopmentFunding
|
19703000 | USD |
| CY2019Q1 | rtrx |
Development Funding Creditable Against Purchase Option
DevelopmentFundingCreditableAgainstPurchaseOption
|
2612000 | USD |
| CY2019Q1 | rtrx |
Development Funding Paid
DevelopmentFundingPaid
|
18299000 | USD |
| CY2018Q1 | rtrx |
Exercise Of Warrants And Reclassification Of Derivative Liability
ExerciseOfWarrantsAndReclassificationOfDerivativeLiability
|
608000 | USD |
| CY2018Q4 | rtrx |
Government Rebates Payable
GovernmentRebatesPayable
|
8464000 | USD |
| CY2019Q1 | rtrx |
Government Rebates Payable
GovernmentRebatesPayable
|
8988000 | USD |
| CY2016Q3 | rtrx |
Lessee Operating Lease Square Footage Leased
LesseeOperatingLeaseSquareFootageLeased
|
45000 | sqft |
| CY2018Q1 | rtrx |
Net Changein Fair Valueof Contingent Consideration
NetChangeinFairValueofContingentConsideration
|
3627000 | USD |
| CY2019Q1 | rtrx |
Net Changein Fair Valueof Contingent Consideration
NetChangeinFairValueofContingentConsideration
|
-14831000 | USD |
| CY2018Q1 | rtrx |
Noncash Interest Expense
NoncashInterestExpense
|
413000 | USD |
| CY2019Q1 | rtrx |
Noncash Interest Expense
NoncashInterestExpense
|
350000 | USD |
| CY2019Q1 | rtrx |
Noncreditable Development Funding Commitment
NoncreditableDevelopmentFundingCommitment
|
17091000 | USD |
| CY2019Q1 | rtrx |
Number Of Products Sold
NumberOfProductsSold
|
3 | product |
| CY2019Q1 | rtrx |
Operating Lease Incentive Tenant Improvements
OperatingLeaseIncentiveTenantImprovements
|
1702000 | USD |
| CY2016Q3 | rtrx |
Operating Lease Incentive Tenant Improvements
OperatingLeaseIncentiveTenantImprovements
|
2300000 | USD |
| CY2019Q1 | rtrx |
Operating Lease Incentive Tenant Improvements
OperatingLeaseIncentiveTenantImprovements
|
1800000 | USD |
| CY2018Q1 | rtrx |
Payment Of Guaranteed Minimum Royalty
PaymentOfGuaranteedMinimumRoyalty
|
500000 | USD |
| CY2019Q1 | rtrx |
Payment Of Guaranteed Minimum Royalty
PaymentOfGuaranteedMinimumRoyalty
|
509000 | USD |
| CY2018Q1 | rtrx |
Provision For Inventory
ProvisionForInventory
|
816000 | USD |
| CY2019Q1 | rtrx |
Provision For Inventory
ProvisionForInventory
|
189000 | USD |
| CY2019Q1 | rtrx |
Remaining Development Funding Payable
RemainingDevelopmentFundingPayable
|
1404000 | USD |
| CY2019Q1 | rtrx |
Straight Line Lease Expense In Excess Of Cash Payments
StraightLineLeaseExpenseInExcessOfCashPayments
|
1635000 | USD |
| CY2018Q1 | rtrx |
Write Off Of Contingent Consideration
WriteOffOfContingentConsideration
|
0 | USD |
| CY2019Q1 | rtrx |
Write Off Of Contingent Consideration
WriteOffOfContingentConsideration
|
18000000 | USD |
| CY2019Q1 | rtrx |
Write Off Of Contingent Consideration
WriteOffOfContingentConsideration
|
18000000 | USD |
| CY2018Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
6954000 | USD |
| CY2019Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
7627000 | USD |
| CY2018Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
12700000 | USD |
| CY2018Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
12662000 | USD |
| CY2019Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
12700000 | USD |
| CY2019Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
12713000 | USD |
| CY2018Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-356000 | USD |
| CY2019Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
343000 | USD |
| CY2018Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
49695000 | USD |
| CY2019Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
46619000 | USD |
| CY2018Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
10446000 | USD |
| CY2019Q1 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
7856000 | USD |
| CY2018Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-1529000 | USD |
| CY2019Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
57000 | USD |
| CY2018Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
589795000 | USD |
| CY2019Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
596644000 | USD |
| CY2018Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4609000 | USD |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
6520000 | USD |
| CY2018Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
0 | USD |
| CY2019Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
2459000 | USD |
| CY2018Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
4199000 | USD |
| CY2019Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
4731000 | USD |
| CY2018Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
10439000 | shares |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
16614000 | shares |
| CY2018Q4 | us-gaap |
Assets
Assets
|
709160000 | USD |
| CY2019Q1 | us-gaap |
Assets
Assets
|
667668000 | USD |
| CY2018Q4 | us-gaap |
Assets Current
AssetsCurrent
|
495678000 | USD |
| CY2019Q1 | us-gaap |
Assets Current
AssetsCurrent
|
475513000 | USD |
| CY2018Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
471541000 | USD |
| CY2019Q1 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
447646000 | USD |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
22000 | USD |
| CY2019Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
484000 | USD |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
1301000 | USD |
| CY2019Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
297000 | USD |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
369947000 | USD |
| CY2019Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
377621000 | USD |
| CY2018Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
368668000 | USD |
| CY2019Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
377800000 | USD |
| CY2019Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
377808000 | USD |
| CY2018Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
208475000 | USD |
| CY2019Q1 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
200834000 | USD |
| CY2018Q4 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
160193000 | USD |
| CY2019Q1 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
176974000 | USD |
| CY2016 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-2300000 | USD |
| CY2017 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-5700000 | USD |
| CY2018Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-4245000 | USD |
| CY2018 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
1000000 | USD |
| CY2019Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-1405000 | USD |
| CY2016Q2 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
25000000 | USD |
| CY2018Q4 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
93000000 | USD |
| CY2019Q1 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
76000000 | USD |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
102873000 | USD |
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
69838000 | USD |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
99394000 | USD |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
61117000 | USD |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
102873000 | USD |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
69838000 | USD |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-38277000 | USD |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-33035000 | USD |
| CY2018Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
0 | shares |
| CY2019Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
0 | shares |
| CY2018Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2019Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2019Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2018Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
41389524 | shares |
| CY2019Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
41438020 | shares |
| CY2018Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
41389524 | shares |
| CY2019Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
41438020 | shares |
| CY2018Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | USD |
| CY2019Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | USD |
| CY2018Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-18892000 | USD |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-39391000 | USD |
| CY2018Q4 | us-gaap |
Convertible Debt Current
ConvertibleDebtCurrent
|
22457000 | USD |
| CY2019Q1 | us-gaap |
Convertible Debt Current
ConvertibleDebtCurrent
|
22537000 | USD |
| CY2018Q4 | us-gaap |
Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
|
195091000 | USD |
| CY2019Q1 | us-gaap |
Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
|
197470000 | USD |
| CY2018Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
1613000 | USD |
| CY2019Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
1017000 | USD |
| CY2018Q1 | us-gaap |
Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
|
15710000 | USD |
| CY2019Q1 | us-gaap |
Debt Instrument Repurchase Amount
DebtInstrumentRepurchaseAmount
|
23400000 | USD |
| CY2018Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
4348000 | USD |
| CY2019Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
4901000 | USD |
| CY2019Q1 | us-gaap |
Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
|
-7500000 | USD |
| CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.46 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.99 | |
| CY2018Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
10000 | USD |
| CY2019Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-21000 | USD |
| CY2018Q1 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-0.013 | |
| CY2019Q1 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-0.010 | |
| CY2018Q4 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
15000000 | USD |
| CY2019Q1 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
15000000 | USD |
| CY2019Q1 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
15000000 | USD |
| CY2018Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
186691000 | USD |
| CY2019Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
159800000 | USD |
| CY2018Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
68952000 | USD |
| CY2019Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
73622000 | USD |
| CY2018Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
255643000 | USD |
| CY2019Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
233375000 | USD |
| CY2019Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
159753000 | USD |
| CY2018Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
22000 | USD |
| CY2019Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
117000 | USD |
| CY2018Q4 | us-gaap |
Goodwill
Goodwill
|
936000 | USD |
| CY2019Q1 | us-gaap |
Goodwill
Goodwill
|
936000 | USD |
| CY2018Q1 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
0 | USD |
| CY2019Q1 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
25500000 | USD |
| CY2018Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-18149000 | USD |
| CY2019Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-40576000 | USD |
| CY2018Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
229000 | USD |
| CY2018Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
200000 | USD |
| CY2019Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
401000 | USD |
| CY2019Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
400000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-9330000 | USD |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-3103000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-886000 | USD |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-40000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
593000 | USD |
| CY2019Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
170000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-421000 | USD |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
9321000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
2211000 | USD |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
9886000 | USD |
| CY2018Q1 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
797000 | USD |
| CY2019Q1 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
2819000 | USD |
| CY2018Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-1155000 | USD |
| CY2019Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-4865000 | USD |
| CY2018Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
930000 | USD |
| CY2019Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
1194000 | USD |
| CY2018Q4 | us-gaap |
Inventory Net
InventoryNet
|
5619000 | USD |
| CY2019Q1 | us-gaap |
Inventory Net
InventoryNet
|
5571000 | USD |
| CY2018Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
4689000 | USD |
| CY2019Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
4377000 | USD |
| CY2018Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
1800000 | USD |
| CY2019Q1 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
1900000 | USD |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
|
0.077 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
14476000 | USD |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
14000000 | USD |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
1585000 | USD |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
2637000 | USD |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
2250000 | USD |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
2560000 | USD |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
2486000 | USD |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
2958000 | USD |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
2530000 | USD |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P5Y | |
| CY2016Q3 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P7Y7M | |
| CY2018Q4 | us-gaap |
Liabilities
Liabilities
|
390907000 | USD |
| CY2019Q1 | us-gaap |
Liabilities
Liabilities
|
381957000 | USD |
| CY2018Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
709160000 | USD |
| CY2019Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
667668000 | USD |
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
104621000 | USD |
| CY2019Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
104075000 | USD |
| CY2018Q4 | us-gaap |
Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
|
93000000 | USD |
| CY2019Q1 | us-gaap |
Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
|
76000000 | USD |
| CY2018Q4 | us-gaap |
Marketable Securities
MarketableSecurities
|
368668000 | USD |
| CY2019Q1 | us-gaap |
Marketable Securities
MarketableSecurities
|
377808000 | USD |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-2702000 | USD |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1110000 | USD |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-20851000 | USD |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-11412000 | USD |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-14734000 | USD |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-20492000 | USD |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18378000 | USD |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-40977000 | USD |
| CY2018Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-237000 | USD |
| CY2019Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2348000 | USD |
| CY2018Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
56344000 | USD |
| CY2019Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
77798000 | USD |
| CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17912000 | USD |
| CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-38228000 | USD |
| CY2019Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
700000 | USD |
| CY2019Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
11946000 | USD |
| CY2019Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
11300000 | USD |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
8609000 | USD |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
7900000 | USD |
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P5Y7M | |
| CY2018Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
7709000 | USD |
| CY2019Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
13471000 | USD |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-536000 | USD |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
1469000 | USD |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-536000 | USD |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
1469000 | USD |
| CY2018Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
6165000 | USD |
| CY2019Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
8292000 | USD |
| CY2018Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
17545000 | USD |
| CY2019Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
23412000 | USD |
| CY2018Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-75000 | USD |
| CY2019Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-62000 | USD |
| CY2018Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
121000 | USD |
| CY2019Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-302000 | USD |
| CY2018Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
39000 | USD |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
19000 | USD |
| CY2018Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2019Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
| CY2018Q1 | us-gaap |
Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
|
7066000 | USD |
| CY2019Q1 | us-gaap |
Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
|
905000 | USD |
| CY2018Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
29519000 | USD |
| CY2019Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
80422000 | USD |
| CY2019Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
80400000 | USD |
| CY2016Q2 | us-gaap |
Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
|
500000 | USD |
| CY2018Q1 | us-gaap |
Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
|
10000000 | USD |
| CY2019Q1 | us-gaap |
Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
|
0 | USD |
| CY2018Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
8217000 | USD |
| CY2019Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
3961000 | USD |
| CY2019Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2019Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2019Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2018Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2019Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2018Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4140000 | USD |
| CY2019Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
8171000 | USD |
| CY2018Q4 | us-gaap |
Prepaid Taxes
PrepaidTaxes
|
1716000 | USD |
| CY2019Q1 | us-gaap |
Prepaid Taxes
PrepaidTaxes
|
1412000 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
608000 | USD |
| CY2019Q1 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
0 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
26924000 | USD |
| CY2019Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
72990000 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
4256000 | USD |
| CY2019Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
304000 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
600000 | USD |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3146000 | USD |
| CY2019Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2995000 | USD |
| CY2018Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
0 | USD |
| CY2019Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
25500000 | USD |
| CY2018Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
24636000 | USD |
| CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
33443000 | USD |
| CY2018Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-270017000 | USD |
| CY2019Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-310994000 | USD |
| CY2018Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
38432000 | USD |
| CY2019Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
39570000 | USD |
| CY2018Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
26468000 | USD |
| CY2019Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
32669000 | USD |
| CY2018Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4659000 | USD |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
116000 | USD |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
175000 | USD |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
4543000 | USD |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
6370000 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
293134000 | USD |
| CY2018Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
299475000 | USD |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
318253000 | USD |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
285711000 | USD |
| CY2018Q1 | us-gaap |
Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
|
22000 | USD |
| CY2019Q1 | us-gaap |
Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
|
117000 | USD |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
39657418 | shares |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
41410314 | shares |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
6271000 | USD |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
5000000 | shares |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
16.92 | |
| CY2018Q1 | us-gaap |
Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
|
4256000 | USD |
| CY2019Q1 | us-gaap |
Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
|
304000 | USD |
| CY2019Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Retrophin, Inc. (“we”, “our”, “us”, “Retrophin” and the “Company”) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with rare diseases and that we believe offer attractive growth characteristics.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">The Company is developing the following pipeline products:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is developing fosmetpantotenate (RE-024), a novel small molecule, as a potential treatment for </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">pantothenate kinase-associated neurodegeneration (“PKAN”)</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">,</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> also known as RE-021, is an investigational product candidate with a dual mechanism of action, a potent angiotensin receptor blocker (“ARB”) and selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A. Sparsentan is currently being evaluated in two pivotal Phase 3 clinical studies in the following indications:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#4c4c4c;font-weight:bold;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Focal segmental glomerulosclerosis ("FSGS") is a rare kidney disease characterized by proteinuria where the glomeruli become progressively scarred. FSGS is a leading cause of end-stage renal disease.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#4c4c4c;font-weight:bold;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Immunoglobulin A nephropathy ("IgAN") is an immune-complex-mediated glomerulonephritis characterized by hematuria, proteinuria, and variable rates of progressive renal failure. IgAN is the most common primary glomerular disease.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is a party to a joint development agreement with Censa Pharmaceuticals Inc. ("Censa"), a privately held biotechnology company focused on developing therapies for orphan metabolic diseases, to evaluate sepiapterin ("CNSA-001") for the treatment of phenylketonuria (PKU). </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In September 2017, the Company entered into a three-way Cooperative Research and Development Agreement ("CRADA") with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) and patient advocacy foundation NGLY1.org to collaborate on research efforts aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">The Company sells the following </font><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">three</font><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;"> products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has been the standard of care for cerebrotendinous xanthomatosis ("CTX") patients for more than three decades and the Company is currently pursuing adding this indication to the label.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola (tiopronin tablets) is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</font></div></td></tr></table></div> |
